Defining the role of mTOR in cancer

Guertin DA, Sabatini DM · 2007 · Cancer Cell · Atlas ID GUE2007

What this study shows

Comprehensive review arguing mTOR signaling is commonly deregulated in human cancers, laying out the rationale for rapalog trials in oncology.

Abstract

ShowHide

The mammalian target of rapamycin (mTOR) has emerged as a critical effector in cell-signaling pathways commonly deregulated in human cancers. This has led to the prediction that mTOR inhibitors may be useful in oncology, and derivatives of one such molecule, rapamycin (from which mTOR derives its name), are currently in clinical development. In this review, we discuss recent progress in understanding mTOR signaling, paying particular attention to its relevance in cancer. We further discuss the use of rapamycin in oncology and conclude with a discussion on the future of mTOR-targeted therapy.

Read the full abstract on PubMed →

At a glance

Evidence type	R Review — secondary literature, not a new result Marked R because it is a review or synthesis of existing evidence rather than a new primary result; that is a different form of writing, not a weaker one.
Study type	Narrative Review
Model system	Review article
Journal	Cancer Cell
Year	2007
Peer reviewed	Yes
Record last updated	2026-10-01
Source	DOI 10.1016/j.ccr.2007.05.008 · PMID 17613433

Extracted findings

These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.

Intervention	Not applicable (review)
Target	mTOR
Model	Review
Effect	Reviews the role of mTOR in cancer and the rationale for rapalog therapy

In the Atlas

Cite this paper

ShowHide

Guertin, D. A., & Sabatini, D. M. (2007). Defining the role of mTOR in cancer. Cancer Cell. https://doi.org/10.1016/j.ccr.2007.05.008

@article{GUE2007,
  author       = {Guertin, D. A. and Sabatini, D. M.},
  title        = {{Defining the role of mTOR in cancer}},
  journal      = {Cancer Cell},
  year         = {2007},
  doi          = {10.1016/j.ccr.2007.05.008},
  note         = {PMID: 17613433},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record GUE2007) [Data set]. https://mtor-atlas.org/study/GUE2007/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_GUE2007,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record GUE2007},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/GUE2007/},
  doi          = {10.5281/zenodo.22059963}
}

Was this page useful?